Neurocrine Biosciences Research and Development Expenses 2010-2024 | NBIX

Neurocrine Biosciences research and development expenses for the twelve months ending June 30, 2024 were $0.630B, a 23.33% increase year-over-year.

  • Neurocrine Biosciences annual research and development expenses for 2023 were $0.565B, a 21.82% increase from 2022.
  • Neurocrine Biosciences annual research and development expenses for 2022 were $0.464B, a 41.36% increase from 2021.
  • Neurocrine Biosciences annual research and development expenses for 2021 were $0.328B, a 19.31% increase from 2020.

Neurocrine Biosciences Research and Development Expenses 2010-2024 | NBIX

  • Neurocrine Biosciences annual research and development expenses for 2023 were $0.565B, a 21.82% increase from 2022.
  • Neurocrine Biosciences annual research and development expenses for 2022 were $0.464B, a 41.36% increase from 2021.
  • Neurocrine Biosciences annual research and development expenses for 2021 were $0.328B, a 19.31% increase from 2020.
Related Stocks
Company NameMarket
Cap
Zoetis (ZTS)$89B
Takeda Pharmaceutical (TAK)$47.2B
Merck (MKGAF)$23.7B
Astellas Pharma (ALPMY)$22.1B
Summit Therapeutics (SMMT)$17.8B
Sandoz Group AG (SDZNY)$17.6B
United Therapeutics (UTHR)$15.2B
Shionogi (SGIOY)$13.1B
Catalent (CTLT)$10.9B
Orion OYJ (ORINY)$7.4B
Revolution Medicines (RVMD)$7.4B
Jazz Pharmaceuticals (JAZZ)$6.8B
Ionis Pharmaceuticals (IONS)$6.2B
Hikma Pharmaceuticals Plc (HKMPF)$5.7B
Madrigal Pharmaceuticals (MDGL)$5.1B
Corcept Therapeutics (CORT)$4.4B
Crinetics Pharmaceuticals (CRNX)$4.2B
Dyne Therapeutics (DYN)$3.4B
PTC Therapeutics (PTCT)$2.7B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.7B
Arrowhead Pharmaceuticals (ARWR)$2.6B
Catalyst Pharmaceuticals (CPRX)$2.4B
Soleno Therapeutics (SLNO)$2.1B
Recursion Pharmaceuticals (RXRX)$1.9B
Centessa Pharmaceuticals (CNTA)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.6B
Xencor (XNCR)$1.6B
Harrow (HROW)$1.6B
Cassava Sciences (SAVA)$1.5B
NewAmsterdam Pharma (NAMS)$1.4B